• Dansk
  • NL
  • EN
  • FI
  • FR
  • DE
  • EL
  • IT
  • NO
  • PL
  • PT
  • RO
  • SL
  • ES
  • SV

Policy prescriptions: the firepower of the EU pharmaceutical lobby and implications for public health

A new report released today reveals the dramatic extent of the pharmaceutical industry's lobbying efforts towards EU decision-makers, with the industry spending an estimated 15 times more than civil society actors working on public health or access to medicines.

'Policy prescriptions: the firepower of the EU pharmaceutical lobby and implications for public health' by Corporate Europe Observatory probes the privileged access to decision-making in Brussels enjoyed by the sector and facilitated by a lobby spend of around €40 million, extensive meetings with policy-makers, and presence in advisory groups. Under-reporting and the continued avoidance by some of the EU's voluntary lobby transparency system mean that overall industry spending may be much higher than the transparency register reveals.

The report shows that Big Pharma enjoys a staggering number of meetings with European Commission departments and officials. For example, influential EU pharmaceutical trade association, the European Federation of Pharmaceutical Industries and Associations (EFPIA), had over 50 meetings with the Juncker Commission in its first four and a half months of office.

The study examines some of Big Pharma’s channels of influence in the EU and exposes concrete examples of EU law and policies that have been targeted or shaped by the industry. These include rules around clinical trials’ data transparency, trade secrets, and the negotiation of the EU-US trade deal, the Transatlantic Trade and Investment Partnership (TTIP).

It also puts pharma lobby group EFPIA in the spotlight, examining its goals, tactics, access and influence, including a critique of the EU’s multi-billion euro public-private partnership with EFPIA, the ‘Innovative Medicines Initiative’.

Report: http://corporateeurope.org/sites/default/files/20150904_bigpharma_web.pdf

Add new comment

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Get our monthly newsletter

Follow us on social media

The European Commission rebranded AirBnB lobbying documents as ‘commercial secrets’ and therefore denied public access. After eight months of wrangling over their release, Corporate Europe Observatory can report the documents show that AirBnB and similar rental platforms are attacking measures used by cities to protect affordable housing.

Industry lobbyists who want to continue monetising users’ online data are battling against new ePrivacy regulations, targeting EU member states in the Council. And some member state governments are only too happy to help.

The EU member state vote on the EU-Japan trade agreement is close, but not all interest groups had an equal say when the deal was hashed out. Official figures from the European Commission show that big business had many more meetings with the EU trade negotiators than small businesses, trade unions and other civil society actors did.

The plastics industry mounted a significant lobby campaign to influence the European Commission’s recent Plastics Strategy. Industry is now seeking to unpick or undermine key elements of the strategy through lacklustre or non-existing voluntary commitments, or outright opposition. With the Commission likely to publish its proposal to tackle single-use plastic products any day, will it adopt an ambitious approach towards binding regulations on industry?

Lobby Planet 2017 banner